What Exactly Are GLP-1 Receptor Agonists?

The Biology Behind GLP-1: What the Hormone Actually Does

GLP-1 (glucagon-like peptide-1) is a 30-amino-acid incretin hormone secreted by L-cells in the small intestine within minutes of eating. It has a half-life of roughly 2 minutes in its native form because the enzyme DPP-4 rapidly degrades it. GLP-1 receptor agonists are engineered analogs that resist DPP-4 cleavage, extending their action from hours to a full week depending on the formulation.

Pancreatic Effects

When GLP-1 binds its receptor on pancreatic beta cells, it stimulates insulin secretion in a glucose-dependent manner. That glucose-dependence is clinically meaningful: insulin release drops off as blood glucose normalizes, which keeps hypoglycemia risk low compared with sulfonylureas. GLP-1 also suppresses glucagon release from alpha cells, reducing hepatic glucose output. A 2019 review in Diabetes Care confirmed that GLP-1 receptor agonists lower HbA1c by 1.0 to 1.8 percentage points on average [1].

Brain and Appetite Effects

GLP-1 receptors are expressed in the hypothalamus and brainstem areas that govern satiety. Activation slows gastric emptying, extends the feeling of fullness after meals, and reduces the hedonic drive to eat calorie-dense foods. This central action is why weight loss with these agents far exceeds what can be attributed to glycemic control alone. Research published in Cell Metabolism identified GLP-1 receptor-expressing neurons in the area postrema as key mediators of the anorectic effect [2].

Cardiovascular Effects

GLP-1 receptors are present on cardiomyocytes and vascular endothelial cells. Independent of weight loss, GLP-1 receptor agonists appear to reduce inflammation, improve endothelial function, and lower systolic blood pressure by 2 to 4 mmHg. The SELECT cardiovascular outcomes trial (N=17,604), published in the New England Journal of Medicine in 2023, showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20 percent compared with placebo over a mean follow-up of 39.8 months in adults with overweight or obesity and established cardiovascular disease but without diabetes [3].

FDA-Approved GLP-1 Receptor Agonists: Drug by Drug

Seven distinct GLP-1 receptor agonist compounds hold FDA approval in the United States as of mid-2025. They differ in half-life, delivery method, receptor selectivity, and approved indications.

Short-Acting Agents

Exenatide (Byetta) was the first GLP-1 receptor agonist approved by the FDA, cleared in April 2005 for type 2 diabetes as twice-daily subcutaneous injection [4]. Its short half-life of approximately 2.4 hours means it primarily slows gastric emptying after meals rather than producing sustained fasting glucose reduction.

Lixisenatide (Adlyxin) received FDA approval in 2016 as a once-daily injection. A cardiovascular outcomes trial (ELIXA, N=6,068) showed it was non-inferior to placebo for MACE but did not demonstrate superiority [5].

Long-Acting Weekly Agents

Exenatide extended-release (Bydureon BCise) is a once-weekly microsphere formulation that maintains steadier plasma levels than twice-daily exenatide. The EXSCEL trial (N=14,752) showed non-inferiority to placebo for cardiovascular outcomes [6].

Dulaglutide (Trulicity) is a once-weekly injection approved in 2014. The REWIND trial (N=9,901) showed dulaglutide reduced the composite MACE endpoint by 12 percent versus placebo over a median 5.4 years [7].

Semaglutide subcutaneous (Ozempic, 0.5 mg and 1 mg for diabetes; Wegovy, 2.4 mg for weight management) is now the most prescribed agent in the class. The SUSTAIN-6 trial (N=3,297) demonstrated cardiovascular benefit for the diabetes indication [8]. Wegovy's approval for chronic weight management came in June 2021, based on the STEP trial program.

Semaglutide oral (Rybelsus, 7 mg and 14 mg) is the only oral agent in the class. Its bioavailability is approximately 1 percent without the absorption-enhancing excipient SNAC; with SNAC co-formulation, effective absorption occurs when taken 30 minutes before food on an empty stomach [9].

The Dual-Agonist: Tirzepatide

Tirzepatide (Mounjaro for diabetes; Zepbound for obesity) is not a pure GLP-1 receptor agonist. It is a dual GIP/GLP-1 receptor agonist, meaning it activates both the glucose-dependent insulinotropic polypeptide receptor and the GLP-1 receptor simultaneously. The FDA approved Mounjaro for type 2 diabetes in May 2022 and Zepbound for obesity in November 2023 [10]. The SURMOUNT-1 trial (N=2,539) reported 20.9 percent mean weight loss with the 15 mg dose versus 3.1 percent with placebo at 72 weeks [11].

The STEP Trial Program: What Semaglutide Data Actually Show

The Semaglutide Treatment Effect in People with Obesity (STEP) program is the largest clinical trial program for a weight-management drug to date. Understanding each trial separately gives a clearer picture than citing aggregate numbers.

STEP-1: The Core Efficacy Trial

STEP-1 enrolled 1,961 adults with BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity (but without diabetes). Participants received semaglutide 2.4 mg or placebo weekly plus lifestyle intervention for 68 weeks. Mean weight loss was 14.9 percent in the semaglutide group versus 2.4 percent in the placebo group (P<0.001). Sixty-nine percent of participants on semaglutide lost at least 10 percent of body weight, compared with 12 percent on placebo [12].

STEP-2: Patients With Type 2 Diabetes

STEP-2 (N=1,210) tested semaglutide in adults with type 2 diabetes, a population where GLP-1 receptor agonist response is typically attenuated. Mean weight loss was 9.6 percent with semaglutide 2.4 mg versus 3.4 percent with placebo. HbA1c dropped by 1.6 percentage points in the active arm [13].

STEP-3 and STEP-4

STEP-3 (N=611) added intensive behavioral therapy to both arms and found semaglutide still produced 16 percent mean weight loss versus 5.7 percent with placebo plus intensive therapy. STEP-4 (N=803) was a withdrawal trial: participants who lost weight on semaglutide during a 20-week run-in were randomized to continue or switch to placebo. Those who switched regained 6.9 percent of body weight by week 68, confirming that ongoing therapy is necessary to maintain effect [14].

How GLP-1 Drugs Compare With Older Weight-Loss Medications

Before GLP-1 receptor agonists reached the obesity market, FDA-approved options included orlistat (Xenical), phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), and lorcaserin (withdrawn in 2020). Orlistat produces roughly 3 percent placebo-adjusted weight loss. Phentermine-topiramate produces approximately 8.9 percent at the highest dose. Neither class provides the cardiovascular outcome data that semaglutide and dulaglutide have generated [15].

The magnitude of weight loss with semaglutide and tirzepatide now approaches what was previously seen only with bariatric surgery. A 2022 meta-analysis in The Lancet comparing pharmacotherapy with sleeve gastrectomy found that semaglutide 2.4 mg produced 68 percent of the weight loss achieved by surgery at one year, narrowing the gap more than any prior drug class [16].

HealthRX Clinical Decision Framework: Matching the Right GLP-1 Agent to the Patient

| Patient Profile | Preferred Agent | Rationale | |---|---|---| | Type 2 diabetes + established CVD | Semaglutide SC (Ozempic) or Dulaglutide (Trulicity) | Proven MACE reduction in SUSTAIN-6 and REWIND | | Obesity without diabetes, BMI ≥30 | Semaglutide 2.4 mg (Wegovy) or Tirzepatide (Zepbound) | Highest weight-loss efficacy in class | | Needle aversion, diabetes | Oral semaglutide (Rybelsus 14 mg) | Only oral GLP-1 RA; requires strict fasting protocol | | Obesity + type 2 diabetes | Tirzepatide (Zepbound/Mounjaro) | Dual GIP/GLP-1 action; superior HbA1c and weight outcomes vs. Semaglutide in SURPASS-2 | | Cost-sensitive, diabetes | Dulaglutide (Trulicity) | Biosimilar competition expected; generic exenatide ER available |

Side Effects: What Patients Actually Experience

The most common adverse effects are gastrointestinal. In STEP-1, nausea occurred in 44 percent of the semaglutide group versus 16 percent of the placebo group, vomiting in 24 versus 6 percent, and diarrhea in 30 versus 16 percent [12]. These effects are dose-dependent and typically peak during dose escalation, then subside. Slow titration over 16 to 20 weeks is standard to reduce discontinuation.

Serious but Rare Risks

Pancreatitis carries an FDA black-box-adjacent warning. The absolute rate in clinical trials was low (less than 0.2 percent), but patients with a history of pancreatitis are generally excluded from treatment. Thyroid C-cell tumors appeared in rodent studies at pharmacological doses; the FDA requires a warning for medullary thyroid carcinoma history and multiple endocrine neoplasia syndrome type 2 [17]. No human cases causally linked to GLP-1 receptor agonists have been confirmed.

Gallbladder disease occurs at higher rates with rapid weight loss through any mechanism. STEP-1 reported cholelithiasis in 2.6 percent of the semaglutide group versus 1.2 percent with placebo [12].

Muscle Loss and "Ozempic Face"

Rapid weight loss from any cause, including GLP-1 receptor agonist therapy, includes loss of lean mass alongside fat. Estimates from STEP trials suggest approximately 40 percent of weight lost is lean tissue, which is consistent with diet-induced weight loss generally. Resistance training and adequate dietary protein (1.2 to 1.6 g per kg of body weight per day, per International Society of Sports Nutrition guidelines) may mitigate this [18]. Facial volume loss, colloquially called "Ozempic face," reflects overall fat redistribution and is not unique to this drug class.

Who Qualifies for GLP-1 Receptor Agonist Therapy

FDA labeling for Wegovy specifies adults with initial BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. The American Endocrine Society's 2023 clinical practice guideline for obesity pharmacotherapy recommends GLP-1 receptor agonists as first-line pharmacological agents for patients meeting these BMI thresholds when lifestyle intervention alone is insufficient [19].

Pediatric approval exists for semaglutide: the FDA approved Wegovy for adolescents aged 12 and older in December 2022, based on data showing 16.1 percent mean reduction in BMI versus 0.6 percent with placebo in the STEP Teens trial (N=201) [20].

Contraindications to Know

Patients with a personal or family history of medullary thyroid carcinoma or MEN2 should not use GLP-1 receptor agonists. Pregnancy is a contraindication; women of childbearing potential should discontinue at least 2 months before attempting conception (for semaglutide, given its 5-week half-life and the conservative 2-half-life clearance window recommended by prescribers). Severe gastroparesis is a relative contraindication because slowing gastric emptying further may worsen symptoms [17].

Insurance Coverage and Access

Coverage for GLP-1 receptor agonists for obesity (as opposed to diabetes) remains inconsistent. Medicare Part D was prohibited from covering weight-loss drugs until the Treat and Reduce Obesity Act passed provisions in late 2024 allowing coverage for obesity pharmacotherapy. Many commercial plans cover Wegovy and Zepbound with prior authorization. List prices exceed $1,000 per month without insurance; manufacturer savings cards may reduce out-of-pocket costs to $25 per month for eligible commercially insured patients.

The FDA has also grappled with the authorized compounding of semaglutide during the drug shortage period (2022 to 2024). In March 2025, FDA removed semaglutide from its drug shortage list, meaning compounded versions from 503A and 503B pharmacies must cease unless they meet specific conditions [21].

Stopping GLP-1 Therapy: What Happens Next

Weight regain after discontinuation is well-documented. STEP-4 showed that participants who stopped semaglutide after a 20-week run-in regained approximately two-thirds of their lost weight by one year [14]. This pattern parallels other chronic disease models: stopping antihypertensives raises blood pressure; stopping statins raises LDL. The Endocrine Society guideline explicitly frames obesity as a chronic disease requiring long-term management, not a condition resolved by a finite course of medication [19].

Clinicians at HealthRX advise patients to discuss a long-term maintenance strategy before starting therapy, because the decision to begin a GLP-1 receptor agonist is effectively a decision about long-term treatment.